Very low-dose dexamethasone to facilitate extubation of preterm babies at risk of bronchopulmonary dysplasia: the MINIDEX feasibility RCT

Author:

Yates Helen1ORCID,Chiocchia Virginia2ORCID,Linsell Louise2ORCID,Orsi Nicolas3ORCID,Juszczak Edmund2ORCID,Johnson Kathryn4,Chetcuti Philip4ORCID,Illingworth Claire5ORCID,Hardy Pollyanna6ORCID,Monk Vaneesha7ORCID,Newell Simon8,Turner Mark9ORCID

Affiliation:

1. Department of Neonatal Medicine, Women and Children’s Hospital, Hull Royal Infirmary, Hull, UK

2. NPEU Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

3. Women’s Health Research Group, Leeds Institute of Cancer and Pathology, St James’s University Hospital, Leeds, UK

4. Leeds Neonatal Service, Leeds General Infirmary, Leeds, UK

5. Patient and public involvement representative

6. Birmingham Clinical Trials Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

7. Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Oxford, UK

8. Leeds Teaching Hospitals NHS Trust, Leeds, UK

9. Neonatal Unit, Liverpool Women’s Hospital, Liverpool, UK

Abstract

Background Postnatal corticosteroids are used to improve lung function and reduce the incidence of bronchopulmonary dysplasia (BPD) in preterm babies. However, corticosteroids may be associated with adverse neurodevelopment. Despite a lack of evidence, some clinicians in the UK use very low-dose regimens of dexamethasone hoping for positive pulmonary effects and optimal neurodevelopment. Objectives To assess the efficacy and safety of very low-dose dexamethasone at facilitating the extubation of ventilator-dependent preterm babies born at < 30 weeks’ gestation and who are at high risk of developing BPD. Design A multicentre, randomised, masked, parallel-group, placebo-controlled Phase 2b trial. The trial was designed as a feasibility study for a subsequent trial of clinical effectiveness. Setting The study was set in 11 tertiary neonatal units in the UK. Participants Ventilator-dependent preterm babies born at < 30 weeks’ gestation aged 10–21 days, receiving at least 30% inspired oxygen and at high risk of developing BPD. Exclusions were babies who had received previous courses of postnatal steroids for respiratory disease; had a severe congenital anomaly affecting the lungs, heart or central nervous system, or had a surgical abdominal procedure or patent ductus arteriosus ligation; and had an illness or medication for which postnatal corticosteroid would be contraindicated (e.g. confirmed or suspected acute sepsis, acute necrotising enterocolitis/focal intestinal perforation or cyclo-oxygenase therapy). Interventions Babies were randomised to very low-dose dexamethasone (50 µg/kg/day for 13 doses) or a matched placebo. Samples of blood and bronchoalveolar lavage fluid from a subset of babies randomised at three participating sites were sent for cytokine analysis at randomisation and at days 5, 7, 10 and 14 of treatment. Primary outcome Time to extubation. Secondary outcomes Secondary outcomes included rates of extubation by day 7 of the intervention; survival to 36 weeks’ postmenstrual age (PMA) or discharge home; respiratory morbidity to 36 weeks’ PMA or discharge home; cytokine profile; safety outcomes; and parent/family experience. Results The main metric of feasibility, namely recruitment, proved difficult. There was a tendency for open-label medication and a higher than predicted rate of suspected/confirmed sepsis among babies. Recruitment was halted after 22 babies had been enrolled. It was found that, compared with the placebo group, a higher proportion of babies were extubated at day 7 of life [5/8 (62.5%) in the very low-dose dexamethasone group vs. 2/6 (33.3%) in the placebo group] and duration of invasive ventilation was lower (a median of 23 days for the very low-dose dexamethasone group vs. a median of 31 days for the placebo group) in the very low-dose dexamethasone group. This is supported by a trend for an increased requirement for open-label rescue steroids in control group babies (41.7% in the very low-dose dexamethasone group vs. 80% in the placebo group). Given the limited sample size, only descriptive statistics can be given; firm conclusions cannot be drawn. Limitations Small sample size and high rates of open-label treatment use. Conclusions It is not feasible to conduct the required pragmatic trial of clinical effectiveness. Future work Assessment of very low-dose dexamethasone in this patient group requires careful consideration. Study registration Clinical Controlled Trials ISRCTN81191607. Funding This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. The report will be published in full in Efficacy and Mechanism; Vol. 6, No. 8. See the NIHR Journals Library website for further project information. The funding for the cytokine analysis is provided by the Children’s Charity Cerebra and is being carried out beyond the lifespan of the NIHR funding.

Funder

Efficacy and Mechanism Evaluation programme

Medical Research Council

Cerebra

Publisher

National Institute for Health Research

Reference39 articles.

1. Boyle EM, Manktelow BN, Field DJ, Oddie S, Draper ES. The Neonatal Survey Report 2012. Leicester: Leicester University. URL: www2.le.ac.uk/departments/health-sciences/research/timms/documents (accessed January 2016).

2. The Canadian Neonatal Network (CNN). CNN 2012 Annual Report. Toronto, ON: CNN; 2012. URL: www.canadianneonatalnetwork.org/Portal (accessed January 2016).

3. Prevention and management of bronchopulmonary dysplasia: lessons learned from the neonatal research network;Kennedy;Semin Perinatol,2016

4. Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease;Greenough;Arch Dis Child,2002

5. Outcomes of extremely low birth weight infants with bronchopulmonary dysplasia: impact of the physiologic definition;Natarajan;Early Hum Dev,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3